The Agency will review supplemental data from AstraZeneca to address ODAC concerns regarding overall survival benefit, trial design interpretation, and cardiovascular safety.
The amount is the first post-trial win for AstraZeneca subsidiary Alexion but is a fraction of the indemnification the ...
AstraZeneca (AZN) stock is in focus as the FDA delays review of a breast cancer therapy containing its next-gen oral SERD ...
Zacks Investment Research on MSN
How did AbbVie's oncology portfolio perform in Q1 despite headwinds?
AbbVie’s ABBV oncology portfolio delivered a slight decline in the first quarter of 2026, as the segment was affected by weak ...
Zacks Investment Research on MSN
FDA extends review time for AZN's camizestrant combo in breast cancer
AstraZeneca AZN announced that the FDA will extend the Prescription Drug User Fee Act (PDUFA) date for reviewing the new drug ...
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
AstraZeneca said the U.S. Food and Drug Administration is pushing back its decision on whether to approve a new breast-cancer drug in order to review additional data provided by the company. The U.K.
AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended its review deadline for its ...
In this video, Lukas Delasos, DO, discusses the biggest takeaways from this year’s European Lung Cancer Congress. Among ...
The firm will evaluate the combination therapy in 80 patients with germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer.
AstraZeneca's Clean Heat Program is turning industrial heat decarbonization into a hedge against energy volatility — and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results